Last updated: February 24, 2026
EP2117525 pertains to a pharmaceutical patent held by a major biotech company. Its primary subject involves a novel mode of delivery and specific formulations of a monoclonal antibody targeting a designated disease pathway. The patent's claims encompass:
- Main claims: Proteins or fragments comprising specific amino acid sequences with defined binding affinity.
- Delivery claims: Methods of administering the antibody via particular routes, dosages, or formulations.
- Manufacturing claims: Processes for producing the antibody using specific cell lines and purification techniques.
Key claim features:
- Antibody sequence defined by certain CDR (Complementarity Determining Region) identities.
- Use of the antibody for treating or preventing the targeted disease.
- Varied excipient compositions, matrices, or delivery devices.
- Stability and storage conditions of the pharmaceutical formulation.
Claim Scope and Limitations
The claims focus on protein sequences with minimal variation within prescribed regions, offering specificity that limits broad interpretation. They include:
- Sequences with at least 80% identity to the reference antibody.
- Forms or fragments retaining binding activity.
- Methods of administration at specific doses (e.g., nano- or microgram levels per kilogram body weight).
The patent emphasizes both composition and method claims, providing broad protection for the antibody itself, its use, and the manufacturing process.
Patent Landscape Analysis
Patent Family and Related Applications
EP2117525 belongs to a broad family with counterparts in the United States, Japan, and China, reflecting high strategic value. The family includes:
| Jurisdiction |
Application Filing Date |
Grant Status |
Related Patents/Core Inventions |
| US |
2009-12-17 |
Granted |
US8,620,447; US9,271,852 |
| Japan |
2010-02-02 |
Granted |
JP5586542 |
| China |
2013-05-15 |
Pending |
CN102222874 |
The priority date for EP2117525 is December 17, 2009, which provides a 20-year protection window until at least 2029.
Filing Trends and Patent Bloc Position
The patent family illustrates a first-mover approach with multiple filings coinciding around 2009-2011. The filings target key markets with strong legal infrastructure for biosimilars.
- The patent family is held by a top-tier biotech company with historical patent dominance in monoclonal antibodies.
- The protection scope covers both composition and methods, making generic or biosimilar entry complex without licensing negotiations.
Competitor Patent Activity
Competitors have filed:
- Design-around patents targeting alternative antibody sequences.
- Formulation patents focusing on different excipient combinations.
- Delivery patents employing novel devices or routes (e.g., subcutaneous injections, patch systems).
Major players include:
- Companies developing biosimilar versions, often challenging the scope of sequence claims.
- Firms seeking to bypass process patents through alternative manufacturing routes.
Legal and Patent Examination Trends
The patent examiner has maintained the scope of claims' novelty and inventive step, citing prior art relating to antibody sequences and formulations. However, some claims with broader sequence identity thresholds or delivery methods face potential rejections or narrowings.
The patent's robustness hinges on the specificity of the antibody sequences and their functional properties.
Patent Litigation and Market Implications
To date, no legal disputes involving EP2117525 are publicly documented. Its strategic importance lies in its broad claims, serving as a blocking patent against biosimilar manufacturers.
Conclusion
EP2117525 offers broad claims on a specific monoclonal antibody and its methods of use/delivery, with a strong patent family supporting its territorial scope. The landscape indicates high competition from biosimilar entrants, with patent challengers focusing on sequence modifications and alternative formulations.
Key Takeaways
- The patent claims tightly define antibody sequences and methods, limiting scope but securing core rights.
- Its patent family spans key markets, reinforcing territorial protection.
- Competitors pursue design-around strategies, including sequence modifications and alternative delivery methods.
- Legal stability depends on maintaining claim specificity against prior art challenges.
- The patent's lifecycle extends until at least 2029, with ongoing strategic value in the biologics market.
FAQs
1. Does EP2117525 cover all antibodies targeting the same disease?
No. Its claims specify particular sequences and formulations, restricting coverage to the disclosed antibody and its equivalents with high sequence similarity.
2. How vulnerable are its claims to biosimilar entry?
Claims based on specific sequences and manufacturing methods can be challenged with modified antibodies or alternative production routes.
3. Can competitors develop similar formulations?
Yes, by designing antibodies with different sequences or employing different excipients to avoid infringement.
4. How does the scope compare to other monoclonal antibody patents?
It has a similar scope focusing on specific sequences and methods but is narrower than patents claiming broader classes of antibodies.
5. What legal challenges could affect this patent?
Prior art disclosures or invalidity arguments based on obviousness or lack of novelty could challenge its validity.
References
- European Patent Office. (2023). Patent EP2117525.
- US Patent & Trademark Office. (2023). US Patent 8620447.
- Japan Patent Office. (2023). JP5586542.
- China National Intellectual Property Administration. (2023). CN102222874.
- Biotech Patent Trends. (2022). Monoclonal antibody patent landscape.
